SUNDAY |
4:00 pm - 8:00 pm | Arrival and Check-in (Check-in Desk Closed 6:00 pm - 7:45 pm) |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 9:30 pm | Keynote Presentations |
| Discussion Leader: Bob Hancock (University of British Columbia) |
7:40 pm - 8:20 pm | Gerry Wright (McMaster University)
"Opportunities for antimicrobial discovery in the resistome"
|
8:20 pm - 8:35 pm | Discussion |
8:35 pm - 9:15 pm | Hiroshi Nikaido (UC Berkeley)
"AcrAB pump of E. coli: a paradigm for MDR efflux pumps of Gram-negative bacteria"
|
9:15 pm - 9:30 pm | Discussion |
MONDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Targeting Gram-positive Pathogens: Discovery and Preclinic |
| Discussion Leader: Jared Silverman (Cubist) |
9:00 am - 9:30 am | Paul Dunman (University of Rochester)
"The RNA degradosome - a rich antibiotic target"
|
9:30 am - 9:40 am | Discussion |
9:40 am - 10:10 am | Suzanne Walker (Harvard University)
"Wall teichoic acid biosynthesis: new targets for antibiotics"
|
10:10 am - 10:20 am | Discussion |
10:20 am | Group Photo / Coffee Break |
10:50 am - 11:20 am | Neil Reiner (University of British Columbia)
"Identification of novel drug targets by exploitation of structural differences in highly conserved proteins between host and pathogen: Pyruvate kinase as a test case"
|
11:20 am - 11:30 am | Discussion |
11:30 am - 12:00 pm | Thomas Keating (Astrazeneca)
"Thymidylate kinase as a novel Gram-positive antibacterial target"
|
12:00 pm - 12:10 pm | Discussion |
| Discussion Leader: Shahriar Mobashery (University of Notre Dame) |
12:10 pm - 12:25 pm | TBA (Poster Talk 1) |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 5:30 pm | Poster Session |
5:30 pm - 7:30 pm | Targeting Gram-positive Pathogens: Compounds in Development |
| Discussion Leader: Jennifer Leeds (Novartis) |
5:30 pm - 6:00 pm | Peter Pertel (Novartis Institutes for BioMedical Research)
"LFF571: A novel compound for the treatment of Clostridium difficile infections"
|
6:00 pm - 6:10 pm | Discussion |
6:10 pm - 6:40 pm | Kelly Aubart (GSK)
"New Peptide Deformylase Inhibitors"
|
6:40 pm - 6:50 pm | Discussion |
6:50 pm - 7:20 pm | Rodger Novak (Nabriva)
"Pleuromutilin antibiotics - 30 years of development, a tale with a surprising turn!"
|
7:20 pm - 7:30 pm | Discussion |
8:00 pm | Dinner |
TUESDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Targeting Gram-negative Pathogens: Discovery and Preclinic |
| Discussion Leader: Heike Broetz-Oesterhelt (University of Düsseldorf) |
9:00 am - 9:30 am | David Livermore (ARMRL)
"Gram-negatives: a hydra-headed challenge"
|
9:30 am - 9:40 am | Discussion |
9:40 am - 10:10 am | Neil Pearson (GSK)
"Optimizing NBTI Activity for Gram-negative infections"
|
10:10 am - 10:20 am | Discussion |
10:20 am | Coffee Break |
10:50 am - 11:20 am | Erin Duffy (Rib-X)
"De novo design of novel ribosomal inhibitors with broadest-spectrum activity"
|
11:20 am - 11:30 am | Discussion |
11:30 am - 12:00 pm | Malcolm Page (Basilea Pharmaceutica)
"Recent progress with beta-lactams"
|
12:00 pm - 12:10 pm | Discussion |
| Discussion Leader: Shahriar Mobashery (University of Notre Dame) |
12:10 pm - 12:25 pm | TBA (Poster Talk 2) |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 5:30 pm | Poster Session |
5:30 pm - 7:30 pm | Targeting Gram-negative Pathogens: Compounds in Development |
| Discussion Leader: Neil Pearson (GSK) |
5:30 pm - 6:00 pm | Justin Montgomery (Pfizer)
"Potent LpxC inhibitors for the treatment of serious Gram-negative infections"
|
6:00 pm - 6:10 pm | Discussion |
6:10 pm - 6:40 pm | John Tomayko (GSK)
"GSK2251052 a boron LeuRS inhibitor: challenges beyond discovery"
|
6:40 pm - 6:50 pm | Discussion |
6:50 pm - 7:20 pm | Daniel Obrecht (Polyphor)
"Targeting outer-membrane transporters of Gram-negative bacteria with Protein Epitope Mimetics"
|
7:20 pm - 7:30 pm | Discussion |
8:00 pm | Dinner |
WEDNESDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Stimulating Host Defense: Vaccines, Antibodies and Peptides |
| Discussion Leader: Bob Hancock (University of British Columbia) |
9:00 am - 9:30 am | Ken Stover (MedImmune)
"Targeting serious bacterial infections with new antibody based strategies"
|
9:30 am - 9:40 am | Discussion |
9:40 am - 10:10 am | Laura Martin (Novartis Vaccines Institute for Global Health)
"Development of conjugate vaccines for enteric fever"
|
10:10 am - 10:20 am | Discussion |
10:20 am | Coffee Break |
10:50 am - 11:20 am | Neeloffer Mookherjee (University Manitoba)
"Cationic host defense peptides: A new paradigm for immunomodulatory therapeutics"
|
11:20 am - 11:30 am | Discussion |
11:30 am - 12:00 pm | Hans-Henrik Kristensen (Novozymes)
"Therapeutic potential of antimicrobial peptides - the plectasin case"
|
12:00 pm - 12:10 pm | Discussion |
| Discussion Leader: Shahriar Mobashery (University of Notre Dame) |
12:10 pm - 12:25 pm | TBA (Poster Talk 3) |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 5:30 pm | Poster Session |
5:30 pm - 7:30 pm | Where Will We Get Our Leads From? |
| Discussion Leader: Lynn Silver (LL Silver Consulting) |
5:30 pm - 6:00 pm | Heinz Moser (Achaogen)
"Property space of antibiotics: Impact on the drug discovery process"
|
6:00 pm - 6:10 pm | Discussion |
6:10 pm - 6:40 pm | Collin Fishwick (University of Leeds)
"Fragment-based molecular design in the discovery of antibacterial drug leads: challenges and opportunities"
|
6:40 pm - 6:50 pm | Discussion |
6:50 pm - 7:20 pm | Stefano Donadio (Naicons)
"New bioactive compounds from Actinobacteria"
|
7:20 pm - 7:30 pm | Discussion |
7:30 pm - 8:00 pm | Business Meeting |
| Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair |
8:00 pm | Dinner |
THURSDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | PK-PD in New Antibacterial Discovery and Development: The Art of the Possible |
| Discussion Leader: Paul Ambrose (ICPD) |
9:00 am - 9:30 am | Sujata M. Bhavnani (ICPD)
"Relationships between antibiotic exposure and early and late efficacy endpoints: What we have learned"
|
9:30 am - 9:40 am | Discussion |
9:40 am - 10:10 am | Christopher M. Rubino (ICPD)
"Leveraging PK-PD relationships to balance the competing needs for high efficacy and low toxicity"
|
10:10 am - 10:20 am | Discussion |
10:20 am | Coffee Break |
10:50 am - 11:20 am | Michael N. Dudley (Rempex Pharmaceuticals)
"But we've never done it that way! Why industry needs to leverage PK-PD approaches to get new antimicrobial agents approved"
|
11:20 am - 11:30 am | Discussion |
| Discussion Leader Eric Brown (McMaster University) |
11:30 am - 11:45 am | TBA (Hot Topic 1) |
11:45 am - 11:50 am | Discussion |
11:50 am - 12:05 pm | TBA (Hot Topic 2) |
12:05 pm - 12:10 pm | Discussion |
| Discussion Leader: Shahriar Mobashery (University of Notre Dame) |
12:10 pm - 12:25 pm | TBA (Poster Talk 4) |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 5:30 pm | Poster Session |
5:30 pm - 7:30 pm | Regulatory Challenges in the Development of Antimicrobial Agents |
| Discussion Leader: David Shlaes (AIC) |
5:30 pm - 5:55 pm | John Rex (Astrazeneca)
"Trial feasibility and relevance of endpoints - the industry view"
|
5:55 pm - 6:00 pm | Discussion |
6:00 pm - 6:25 pm | Edward Cox (Director of the Office of Antimicrobial Products, FDA)
"The FDA - where do we go from here?"
|
6:25 pm - 6:30 pm | Discussion |
6:30 pm - 6:55 pm | Mair Powell (MHRA: Chair EMA Infectious Disease Working Party)
"New EU guidance on antibacterial drug development 2011-2012"
|
6:55 pm - 7:00 pm | Discussion |
7:00 pm - 7:30 pm | Panel Discussion lead by David Shlaes (AIC) |
8:00 pm | Dinner |
FRIDAY |
7:30 am - 8:30 am | Breakfast |
9:00 am | Departure |